NCT06550128 - Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB). | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

February 2, 2026

Study Completion Date

June 30, 2026

Conditions

Hepatitis B, Chronic

Interventions

DRUG

AHB-137

AHB-137 injection will be administered subcutaneously.

DRUG

AHB-137 and Placebo

AHB-137and placebo will be administered subcutaneously.

DRUG

AHB-137 (16weeks)

AHB-137 injection will be administered subcutaneously.

Trial Locations (6)

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou

The third People's Hospital of Zhenjiang, Zhenjiang

Beijing Friendship Hospital, Capital Medical University, Beijing

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

Nanfang Hospital, Southern Medical University, Guangzhou

The First Hospital of Jilin University, Jilin

All Listed Sponsors

lead

Ausper Biopharma Co., Ltd.

INDUSTRY